Additionally, the finerenone structure confers higher selectivity for the MR and minimizes off-target effects on androgen, progesterone, estrogen, and glucocorticoid receptors, which results in a lower incidence of adverse effects such as gynecomastia observed with steroidal MRAs like spironolactone (51). This evidence concerns the gene NR3C1 and Gynecomastia.